SEC Form 10-Q filed by Aardvark Therapeutics Inc.
$AARD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2026 | $32.00 | Buy | B. Riley Securities |
| 12/23/2025 | $35.00 | Outperform | Oppenheimer |
| 12/12/2025 | Outperform | William Blair | |
| 12/3/2025 | $47.00 | Strong Buy | Raymond James |
| 11/7/2025 | $26.00 | Buy | BTIG Research |
| 9/29/2025 | $24.00 | Buy | Stifel |
| 6/30/2025 | $40.00 | Buy | H.C. Wainwright |
| 3/10/2025 | $29.00 | Overweight | Morgan Stanley |
B. Riley Securities initiated coverage of Aardvark Therapeutics with a rating of Buy and set a new price target of $32.00
Oppenheimer initiated coverage of Aardvark Therapeutics with a rating of Outperform and set a new price target of $35.00
William Blair initiated coverage of Aardvark Therapeutics with a rating of Outperform
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that it has established Ardia Therapeutics, Inc. (Ardia), a new wholly-owned U.S. subsidiary. Ardia will support development of a new dermatology pipeline focused on lead asset, DIA-615, a potential topical treatment for a variety of inflammatory skin diseases, including psoriasis. Bryan Jones, Ph.D., has been named Chief Executive Officer of Ardia and has transitioned out of his current role at Aar
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that Institutional Review Board (IRB) approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome (PWS). The amended protocol, submitted to the U.S. Food and Drug Administration (FDA), lowers the minimum age of eligibility for trial participation
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. "It's an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS," said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. "The United in